跳至主要内容
临床试验/EUCTR2008-003362-26-DE
EUCTR2008-003362-26-DE进行中(未招募)不适用

A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in anexpanded flora test with healthy subjects - Marples Kligman Test

Almirall Hermal GmbH0 个研究点开始时间: 2008年7月1日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • men and women aged 18 to 45 years;
  • healthy skin in the area of the test fields;
  • the physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study;
  • female volunteers of childbearing potential must either be surgically sterile (hysterectomy or tubal ligation) or agree to use a reliable method of contraception with a failure rate of less than 1 % per year when used consistently and correctly such as implants, injectables, combined oral contraceptives, some intra uterine devices [IUDs], sexual abstinence or vasectomized partner.
  • written informed consent obtained.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Subjects are to be excluded from the study when one or more of the following conditions are met:
  • acne, suntan, eczema, hyperpigmentation or tattoos in the test fields;
  • evidence of drug or alcohol abuse;
  • pregnancy or nursing;
  • symptoms of a clinically significant illness that may influence the outcome of the study in the four weeks before and during the study;
  • treatment with any other investigational drug in the four weeks preceding the study;
  • known allergic reactions to components of the study preparations; hypersensitivity against cetylstearyl alcohol;
  • treatment with systemic or locally acting medications which might counter or influence the study aim within two weeks before the beginning of the study (e.g. antihistamines or glucocorticosteroids);
  • contraindications according to summary of product characteristics;
  • in the opinion of the investigator or physician performing the initial examination the subject should not participate in the study, e.g. due to probable noncompliance or inability to understand the study and give adequately informed consent;
  • subject is institutionalized because of legal or regulatory order.

研究者

相似试验

进行中(未招募)
1 期
A phase IIa single-center, randomized, controlled, observer-blind study to investigate the antimicrobial efficacy of topical formulations containing octenidine and prednicarbate in an expanded flora test with healthy subjects - Marples Kligma
EUCTR2009-009948-23-DEAlmirall Hermal GmbH20
进行中(未招募)
不适用
A phase II, single-center, randomized, controlled, observer-blind study to determine the non-inferiority of a topical mometasone formulation vs a marketed comparator by evaluation of the anti-psoriatic efficacy in a psoriasis plaque test
EUCTR2008-002141-24-DEAlmirall Hermal GmbH
进行中(未招募)
不适用
A phase II, single-center, randomized, controlled, observer-blind study with intra-individual comparisons within two parallel groups to assess the efficacy of a topical Aescin formulation in the treatment of allergic contact dermatitissubjects with proven nickel allergy
EUCTR2009-009379-36-DEMarinomed Biotechnologie GmbH40
进行中(未招募)
不适用
A phase II, single-center, randomized, controlled, double-blind study to assess effects on skin conditions and patient reported outcome of a topical formulation containing LAS41002 on lesional skin in patients with atopic eczema - ADClinical condition of atopic eczema mild to moderate defined by a local SCORAD of at least 5 with •erythma = 2•lichenification = 1•dryness = 1 •itching = 1•Erlangen atopy score sum equal or higher than 10 pointsMedDRA version: 12.1Level: LLTClassification code 10003639Term: Atopic dermatitis
EUCTR2009-017407-28-DEAlmirall Hermal GmbH
进行中(未招募)
不适用
A phase IIa, single-center, randomized, reference-controlled, observer-blind trial to assess the efficacy of a topical Aescin formulation in experimentally induced itch, wheal and flare reactions in patients with type-I allergy
EUCTR2010-019373-15-DEMarinomed Biotechnologie GmbH40